January 22, 2008

HCL partners with Visiprise

HCL Technologies Ltd (HCL) has announced that the Company has entered into a global consulting partnership with Visiprise, Inc. for the Life Sciences industry, covering all aspects of the medical device manufacturing cycle. Visiprise provides manufacturing execution solutions (MES) that help global manufacturers to gain visibility into operations, achieve shop floor control and manage product and process traceability. The consulting agreement will include joint marketing, sales and pre-sales services and will result in the ability for seamless licensing, blueprinting, implementation, plant-business integration, roll out, support, upgrade / migration and instance consolidation services to manufacturers.

The strategic partnership will further strengthen HCL's position as "Innovators / leaders" in the Manufacturing IT landscape with initial focus on medical devices further expanding to Hitech, Aerospace, Auto and other discrete industries. Under this agreement Visiprise will also be training and certifying HCL consultants on Visiprise solutions.

Speaking on the occasion Mr. Pradep Nair, VP, Global Life Sciences and Healthcare practice, of the Company said, "With increasing global competition, it is imperative for manufacturers to innovate faster, cheaper, with sustained / better quality meeting stringent regulatory norms. Manufacturers are therefore making strategic investments in comprehensive IT solutions focused towards improving efficiency in the plant operations and Increasing collaboration between engineering, enterprise and plant functions as well as extended eco systems such as partners and suppliers. HCL's partnership with Visiprise is well poised in bringing about the transformational change in plant operations. We believe that Visiprise's technology and strategic alignment with SAP and PLM vendors will help customers in seamless business integration from shop-floor to top-floor, which aligns well with HCL's focus towards Manufacturing IT solutions and services."

No comments: